Market closed
Kalaris Therapeutics/$KLRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kalaris Therapeutics
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
Ticker
$KLRS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
KLRS Metrics
BasicAdvanced
$125M
-
-$10.44
-
-
Price and volume
Market cap
$125M
52-week high
$12.90
52-week low
$5.87
Financial strength
Current ratio
0.105
Quick ratio
0.066
Total debt to equity
-39.327
Interest coverage (TTM)
-1.27%
Management effectiveness
Return on assets (TTM)
-681.04%
Return on equity (TTM)
270.05%
Valuation
Price to book
-0.47
Price to tangible book (TTM)
-0.47
Price to free cash flow (TTM)
-2.148
Growth
Earnings per share change (TTM)
330.98%
KLRS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kalaris Therapeutics stock?
Kalaris Therapeutics (KLRS) has a market cap of $125M as of April 27, 2025.
What is the P/E ratio for Kalaris Therapeutics stock?
The price to earnings (P/E) ratio for Kalaris Therapeutics (KLRS) stock is 0 as of April 27, 2025.
Does Kalaris Therapeutics stock pay dividends?
No, Kalaris Therapeutics (KLRS) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Kalaris Therapeutics dividend payment date?
Kalaris Therapeutics (KLRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) does not currently have a Beta indicator.